Crystal Gadegbeku, MD
Nephrology · Philadelphia, PANPI 1013099910
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,648 of the $5,107 with a category attached, or 91.0%. Vertex accounts for 91.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,648, more than ten times the $54 reported in 2020.
Across 10 payments — averaging $510.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$5K
- Amgen$121
- Bayer$120
- Novo Nordisk$116
- AstraZeneca$70
- Aurinia Pharma U.S., Inc.$28
- plus $6 from 1 others
Across 38 payments — averaging $1506.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$56K
- Vertex$1K
What the payments were for
- Consulting fees$4,64891%
- Food & beverage$4599%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 1 | $4,648 |
| Amgen(2 entities) | 3 | $121 |
| Bayer | 1 | $120 |
| Novo Nordisk | 1 | $116 |
| AstraZeneca | 2 | $70 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Travere Therapeutics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,107 in reported general payments places this provider in the 85th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $14,791 |
| Telmisartan | 18 | $169 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $166 |
| Allopurinol | 30 | $139 |
| Amlodipine Besylate | 32 | $122 |
| Losartan Potassium | 12 | $96 |
| Carvedilol | 15 | $88 |
| Furosemide | 13 | $68 |
| Lisinopril | 33 | $34 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.